Identification of type 3 fimbriae in uropathogenic Escherichia coli reveals a role in biofilm formation.
Catheter-associated urinary tract infection (CAUTI) is the most common nosocomial infection in the United States. Uropathogenic Escherichia coli (UPEC), the most common cause of CAUTI, can form biofilms on indwelling catheters. Here, we identify and characterize novel factors that affect biofilm formation by UPEC strains that cause CAUTI. Sixty-five CAUTI UPEC isolates were characterized for phenotypic markers of urovirulence, including agglutination and biofilm formation. One isolate, E. coli MS2027, was uniquely proficient at biofilm growth despite the absence of adhesins known to promote this phenotype. Mini-Tn5 mutagenesis of E. coli MS2027 identified several mutants with altered biofilm growth. Mutants containing insertions in genes involved in O antigen synthesis (rmlC and manB) and capsule synthesis (kpsM) possessed enhanced biofilm phenotypes. Three independent mutants deficient in biofilm growth contained an insertion in a gene locus homologous to the type 3 chaperone-usher class fimbrial genes of Klebsiella pneumoniae. These type 3 fimbrial genes (mrkABCDF), which were located on a conjugative plasmid, were cloned from E. coli MS2027 and could complement the biofilm-deficient transconjugants when reintroduced on a plasmid. Primers targeting the mrkB chaperone-encoding gene revealed its presence in CAUTI strains of Citrobacter koseri, Citrobacter freundii, Klebsiella pneumoniae, and Klebsiella oxytoca. All of these mrkB-positive strains caused type 3 fimbria-specific agglutination of tannic acid-treated red blood cells. This is the first description of type 3 fimbriae in E. coli, C. koseri, and C. freundii. Our data suggest that type 3 fimbriae may contribute to biofilm formation by different gram-negative nosocomial pathogens.
School of Molecular and Microbial Sciences, Centre for Microscopy and Microanalysis, University of Queensland, Brisbane, Australia.
Cheryl-Lynn Y
CL
Ong
Glen C
GC
Ulett
Amanda N
AN
Mabbett
Scott A
SA
Beatson
Richard I
RI
Webb
Wayne
W
Monaghan
Graeme R
GR
Nimmo
David F
DF
Looke
Alastair G
AG
McEwan
Mark A
MA
Schembri
D016667:Bacterial Capsules / Q000096:biosynthesis; D018441:Biofilms / Q000254:growth & development*; D004926:Escherichia coli / Q000235:genetics / Q000254:growth & development* / Q000648:ultrastructure; D004927:Escherichia coli Infections / Q000382:microbiology; D029968:Escherichia coli Proteins / Q000235:genetics / Q000378:metabolism; D010861:Fimbriae, Bacterial / Q000145:classification* / Q000235:genetics / Q000378:metabolism* / Q000648:ultrastructure; D006801:Humans; D008855:Microscopy, Electron, Scanning; D008969:Molecular Sequence Data; D019081:O Antigens / Q000096:biosynthesis; D010802:Phylogeny; D017422:Sequence Analysis, DNA; D014546:Urinary Catheterization / Q000009:adverse effects*; D014552:Urinary Tract Infections / Q000382:microbiology*
D029968:Escherichia coli Proteins; D019081:O Antigens